Frequency and activity of autorosette forming cells in Con-A activated PBL from women with hyperplasia or carcinoma of the endometrium--possible role of estrogens.
In a previous study we showed that endometrial carcinoma (EC) patients have a T cell deficiency manifested in a reduced ability to be stimulated in vitro by PHA and to produce IL-2. In an attempt to understand the mechanism responsible for this alteration we present in this paper a study on T cells characterized by the ability to form rosettes, with human erythrocytes, following Con-A activation (designated auto-rosette forming cells--ARFC). These cells are also known to manifest suppressive activity. We show that the frequency of ARFC in con-A activated peripheral blood leukocytes (PBMC) of EC patients is significantly (2-5 fold) higher than that of healthy age-matched controls or that of patients with stage--I colon or vaginal cancer. Endometrial carcinoma is known to be associated with long term exposure to estrogens unopposed by progestins. Examining the possible role of estrogens in increasing the frequency of ARFC from EC patients, we found that in vitro addition of estradiol to Con-A stimulated PBMC from healthy donors increased the frequency of ARFC to levels found in EC patients. Tamoxifen, an anti estrogen drug, reduced the frequency of the estrogen stimulated ARFC to the original low level. Our results suggest a dual role for estrogen in carcinogenesis as well as in immunomodulation.
Yron
I
I
Department of Microbiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.
Kalechman
Y
Y
Langer
A
A
Lidor
I
I
Luria
B
B
Luria
H
H
Ovadia
J
J
Pardo
Y
Y
Shohat
L
L
D003208:Concanavalin A / Q000276:immunology; D004714:Endometrial Hyperplasia / Q000276:immunology*; D004958:Estradiol / Q000494:pharmacology; D004967:Estrogens / Q000276:immunology*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008875:Middle Aged; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D013629:Tamoxifen / Q000494:pharmacology; D014594:Uterine Neoplasms / Q000276:immunology*
D004967:Estrogens; D013629:Tamoxifen; D003208:Concanavalin A; D004958:Estradiol